Treatment with 5-alpha-reductase inhibitors (5-ARIs) is associated with shorter time to diagnosis and worse mortality in prostate cancer, according to findings from Veterans Affairs electronic health records.
Reuters Health Information
Treatment with 5-alpha-reductase inhibitors (5-ARIs) is associated with shorter time to diagnosis and worse mortality in prostate cancer, according to findings from Veterans Affairs electronic health records.
Reuters Health Information
